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IN JULY, GLOBAL HEADLINES PROCLAIMED 
that a “fl ab jab” was imminent, an obesity vac-
cine that would allow consumption of endless 
fast and fatty foods without punishing weight 
gain. The proof: Mice that were injected with 
a vaccine targeting the hormone somatostatin 
gorged on a high-fat diet with signifi cantly 
less weight gain than those given a sham 
injection. “Thousands of people contacted us 
volunteering for clinical trials. Everyone from 
mothers wanting to lose baby fat to weight 
lifters in Germany,” says vaccinologist Keith 
Haffer of small, South Dakota–based Braasch 
Biotech, who led the rodent study.
With funding interest from several South 
American companies, Braasch Biotech 
does plan to begin human clinical trials of 
its somatostatin vaccine late in 2013. Hold 
the extra cheese on that large sausage pizza, 
however. It’s diffi cult enough to develop and 
obtain approval for a traditional vaccine 
against a bacterium or virus, let alone create 
one that rouses the immune system to target 
molecules that drive a chronic disease such as 
obesity. Indeed, potential vaccines for hyper-
tension, asthma, Alzheimer’s disease, obesity, 
and smoking (because it is a risk factor for 
heart disease, cancer, stroke, and more) have 
all been hyped for their promise in recent 
years and then suffered high-profi le failures. 
In 2002, for example, a vaccine that raised 
antibodies to the β-amyloid protein that accu-
mulates in the brains of people with Alzheim-
er’s disease suffered a scary setback when 
6% (18 of 298) of the clinical trial subjects 
receiving the AN1792 vaccine developed a 
severe brain infl ammation. And Nabi Bio-
pharmaceuticals’s nicotine vaccine, designed 
to suck the high out of smoking, failed in a 
Phase III trial last year. Switzerland-based 
Cytos Biotechnology also attempted vaccines 
for smoking, as well as hypertension and type 
2 diabetes, and though its researchers made 
progress, the company ran out of funding in 
2011 and abandoned most of those efforts. 
Vaccine developers also face a “psychoso-
cial” problem, says Kim Janda, a chemist at 
the Scripps Research Institute in San Diego, 
California, who has worked on vaccines for 
obesity, smoking, and addictive drugs for 
the past 30 years. “In large part, society still 
views addiction or even obesity as a moral 
failure rather than a chronic disease.” It’s dif-
fi cult to persuade drug companies and the 
general population to invest in treating some-
thing they view as a failure of willpower with 
an intervention like a vaccine, Janda says. 
But he isn’t giving up and neither are oth-
ers. “If you can fi nd a target that is the under-
lying cause” of an illness, Janda says, “then 
you can develop a vaccine for its treatment.” 
There are now a number of vaccines in clini-
cal trials for cancer, which is considered a 
chronic disease, Janda says, so why not ones 
for obesity, diabetes, and drug abuse?
“We know why we failed previously and 
that there are clear pathways in front of us,” 
adds Martin Bachmann, an immunologist 
formerly with Cytos Biotechnology. He says 
that poor antibody responses and lack of 
specifi city—critical fl aws for a vaccine—are 
problems that companies are now addressing 
by using full-length proteins, rather than pep-
tides, and experimenting with viruslike par-
ticles that yield a higher and more consistent 
antibody response. 
Mite-y vaccine
Vaccines were originally developed to com-
bat microbial pathogens such as the small-
pox virus and the tuberculosis bacterium; 
people are traditionally injected with live or 
dead copies of a pathogenic microbe, or with 
its molecular components—a viral surface 
protein, for example—to rally the immune 
system to produce antibodies or cells that 
specifi cally target the invader for destruction. 
Yet vaccines may be able to do more than 
prevent infections. Consider asthma, the target 
of one vaccine effort. Worldwide, 
more than 300 million people suf-
fer from asthma, often sparked 
by a violent immune response to 
common environmental allergens. 
Current treatments include corti-
costeroids, which reduce infl am-
mation but have side effects, and 
a procedure called desensitization 
in which asthma/allergy patients 
are given increasing doses of an 
allergen cocktail. But the success 
of desensitization varies from per-
son to person and occasionally 
causes a life-threatening reaction: 
anaphylaxis. 
A team led by Bruno Pitard at 
the University of Nantes in France 
is now tackling asthma with a 
Mite-y vaccine. Dust mites such as Dermatophagoides farinae 
(pictured) are a trigger of allergies and asthma, prompting efforts 
to immunize people against one of their proteins. 
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variation on the traditional vaccine. Pitard’s 
strategy stems from the observation that 50% 
of Europeans with allergies harbor antibodies 
against the Der f 1 protein from Dermatopha-
goides farinae, one of the most common 
dust mites in the United States and Europe. 
But instead of immunizing with actual Der f 
1 proteins from this mite, which can trigger 
an allergic response in people with asthma, 
Pitard and his colleagues are test-
ing a vaccine composed of DNA 
coding for the protein, with the idea 
that it would train the immune sys-
tem to tolerate it. 
When naked DNA is injected 
into the body, however, it is rap-
idly degraded before it can express 
the antigen it encodes. That prob-
lem has frustrated many develop-
ing naked DNA vaccines, so Pitard 
is now treating his Der f 1 DNA 
with so-called tetrafunctional block 
copolymers, which, as his team dis-
covered in 2009, encourage gene 
delivery into the skeletal mus-
cle, where the protein can then be 
manufactured. The team recently 
immunized mice using this modi-
fi ed vaccine, and those mice had a 
fi vefold reduction in their asthmatic 
reaction, Pitard says. Lung tissue 
and bronchioles carried far fewer 
infl ammatory cells and cytokines 
than in asthmatic mice vaccinated with a pla-
cebo. Despite that encouraging data, it will be 
at least 5 years before a clinical trial of the 
asthma vaccine begins, Pitard predicts. 
Most candidate vaccines for chronic dis-
eases don’t target microbial molecules but 
proteins made by the human body. Take the 
strategy behind the original Alzheimer’s dis-
ease vaccine, which sought to activate the 
immune system against β amyloid. Because 
of the dangerous brain infl ammation that fol-
lowed, companies have largely turned to a 
so-called passive immunization, an approach 
in which they create antibodies targeting β 
amyloid outside the body, then inject them 
(Science, 17 August, p. 790). But several 
companies are still studying vaccines against 
different forms of β amyloid, which they 
hope will not produce the same side effects. 
The various obesity vaccines also go 
after natural human proteins. Somatostatin, 
a small peptide hormone produced in the 
hypothalamus, inhibits growth hormone and 
insulin-like growth factor, which increase 
metabolism. The interest in a somatostatin 
vaccine for humans began when Haffer was 
searching for another use for Braasch Bio-
tech’s vaccine Somatovac, which they found 
was a promising way to boost milk produc-
tion in cows and lean meat production in 
pigs without using bovine growth hormone 
or antibiotics. He realized that Somatovac 
might also promote leanness in humans and 
therefore fi ght obesity. 
Haffer sent two different versions of the 
somatostatin vaccine to Jackson Laboratory 
in Bar Harbor, Maine, where researchers 
there tested them on mice that had previously 
bulked up from consuming a high-fat diet for 
8 weeks. Neither vaccine made the already-
plump rodents lose weight, but they gained 
10% less weight than control rodents, even 
though all the animals ate the same quan-
tity of high-fat food during the 6-week study, 
Haffer reported in July in the Journal of 
Animal Science and Biotechnology. 
The concept of creating vaccines for dis-
eases like obesity isn’t outlandish, but choos-
ing the target is tricky, says George Jackson 
of the University of Texas Medical Branch in 
Galveston, a neuroscientist who is working 
on a next-generation vaccine for Alzheimer’s 
disease. With Alzheimer’s, he points out, you 
could potentially “target Mr. Hyde without 
harming Dr. Jekyll” because the culprit—a 
rogue form of β amyloid—appears to have no 
benefi cial role. Obesity is different, he says: 
“Somatostatin is doing something bad but 
also something good. A vaccine could cause 
side effects by interfering with that normal 
function.” Immunizing against an endog-
enous hormone controlling appetite might 
cause anorexia or wasting away, for example.
Haffer isn’t the fi rst to dream of an obesity 
vaccine. Janda and others have targeted the 
appetite-stimulating hormone ghrelin in their 
attempts to build an obesity vaccine. Back in 
2006, Janda made headlines similar to those 
received by Haffer’s work when he and col-
leagues reported that vaccinating adult male 
rats with a segment of ghrelin protein, or the 
full-length version, slowed weight gain and 
fat buildup in the body but didn’t seem to 
affect appetite. Janda cautioned at the time 
that the study rats dined on a mundane, low-
fat, low-energy chow. He couldn’t predict 
from this study whether the vaccine would 
prevent diet-induced obesity—the kind that 
affl icts many people consuming a high-fat 
Western diet—or trigger weight loss in ani-
mals that were already obese.  
Mariana Monteiro, an endocrinologist 
at the University of Porto in Portugal, pre-
sented more evidence at The Endocrine Soci-
ety’s Annual Meeting in June 2011 that an 
antighrelin vaccine could reduce appetite-
promoting brain chemicals in mice. She 
revealed that tethering ghrelin to a viral pro-
tein could trigger enough antighrelin antibod-
ies in the rodents to reduce eating, increase 
energy use, and reduce levels of neuropeptide 
Y—a potent appetite stimulator. But there 
was no overall weight loss at the end of the 
study. Monteiro wrote in October 2011 in 
Expert Review of Vaccines that the under-
whelming impact on long-term food intake 
and body weight “might be due to activation 
of compensatory mechanisms.”
Janda and his team have also explored pas-
sive immunization: injecting antighrelin anti-
bodies in mice. In a study published in Feb-
ruary in Molecular Pharmaceutics, Janda’s 
team showed that a cocktail of three mono-
clonal antibodies targeting ghrelin could 
curb appetite and increase energy use. While 
this isn’t really a ghrelin vaccine because it 
bypasses the immune system, it similarly 
“protects” the mice from the hormone and 
dulls its role as an appetite stimulant. 
Even with expanding numbers of over-
weight and obese people worldwide, Janda’s 
results so far haven’t secured him National 
Institutes of Health funding to further 
develop a ghrelin vaccine. He’s skeptical 
himself about tackling obesity this way. “I 
don’t think there is one controlling molecule 
for metabolism,” he says. “It’s not going to 
be a panacea for all obesity.” 
Bachmann suspects that trying to develop 
a vaccine for obesity is hopeless. “It’s so com-
Vaccine recipe. First produce a viruslike particle, then 
chemically link multiple copies of an antigen, such as 





















































plicated,” he says, “and people love to eat.” 
An obesity vaccine is fi ghting all the evolu-
tionary safeguards that encourage an animal 
to eat and ward off starvation. He’s also not 
convinced that mice are a reliable indicator 
of whether an obesity vaccine will work in 
humans, noting that “every animal has differ-
ent feeding behavior.” 
Nullifying nicotine
Bachmann remains more optimistic about 
a potential nicotine vaccine that could help 
people stop smoking, even though those 
efforts, too, have stumbled. A nicotine vac-
cine is subtly different from—and potentially 
safer than—those targeting obesity-related 
molecules or Alzheimer’s disease protein. 
The strategy, as with other so-called addiction 
vaccines for heroin and cocaine, is to create 
enough antinicotine antibodies in the blood 
to diminish the amount of the compound that 
makes it to the brain, in theory making an 
individual cigarette less appealing. Nicotine 
isn’t normally in the body, so there arguably 
should be less risk of side effects from induc-
ing antibodies that block it.
In the late 1990s, scientists at Nabi devel-
oped and began testing NicVAX, a traditional 
conjugate vaccine that tethered nicotine, 
which by itself is so small that it’s invisible 
to the immune system, to a readily detected 
bacterial protein. Animal studies were prom-
ising: The vaccine stimulated the production 
of antibodies that bound much of the nicotine 
in the blood before it reached the brain, sup-
pressing the pleasurable nicotine high.  
The initial clinical trials examining 
NicVAX’s safety revealed no significant 
concerns, and by late 2007 Nabi announced 
that additional Phase II trials had allowed 
it to zero in on the most effective vaccine 
dose. The company also found that among 
the vaccinated smokers, the antibody 
response correlated closely with the ability 
to quit and remain abstinent. Late last year, 
however, the happy ending did not material-
ize. Nabi announced that its Phase III trial 
of NicVAX was a failure: There wasn’t a 
signifi cant difference between the percent-
age of quitters in the NicVAX group and the 
placebo group.  
Others are also fi nding an anti-smoking 
vaccine elusive. In 2008, Bachmann and his 
colleagues at Cytos tested their own nico-
tine vaccine in 341 smokers in a 6-month 
randomized, controlled Phase II clinical 
trial; 229 were given the vaccine while 112 
received the placebo, administered monthly. 
After 2 months, the number of quitters in 
the vaccine group was signifi cantly higher 
than the placebo group, 47% versus 35%. 
But after 6 months, the difference 
between the two groups was negligible. A 
closer look at the data offered some hope: 
The “high responders,” the people who pro-
duced the highest levels of antinicotine anti-
body in response to the vaccine, enjoyed 
the greatest success. Of the high respond-
ers, 57% had abstained from smoking after 
6 months, compared with 31% of the pla-
cebo group. At 1 year, the numbers dropped 
to 41% and 21%, respectively, which Bach-
mann calls “statistically and clinically sig-
nifi cant.” “Only one-third of the patients had 
a high antibody response,” he says. “If we 
could improve that by a factor of 3, then we 
might have a product.” 
Vaccine development is an expensive 
game, however, and Cytos 
ran out of money a year 
ago. Bachmann has since 
launched two companies, 
Areba and Saiba, which 
focus on vaccines for Par-
kinson’s disease, malaria, 
and Alzheimer’s disease. 
“I don’t have the money 
to do smoking,” he says, 
though he is still a “great 
believer” in the nicotine 
vaccine. 
Producing enough 
antibodies to bind to the 
500 micrograms of nico-
tine in a cigarette before 
it crosses the blood-brain 
barrier in 6 to 10 sec-
onds is a formidable hur-
dle. One radical strategy 
to meet that challenge, 
described on 27 June in 
Science Translational 
Medicine, is more akin to 
gene therapy than a vac-
cine. Janda and collabora-
tor Ronald Crystal, a pul-
monologist and genetic 
medicine expert at Weill 
Cornell Medical College 
in New York City, injected 
mice with a virus that trav-
els to the liver, carrying 
the gene for a monoclonal antibody with a 
high affi nity for nicotine. There, infected cells 
release antinicotine antibodies into the blood.
“When you give nicotine to mice, they 
chill out like people,” Crystal says. Their 
blood pressure and heart rate drop by almost 
half within 25 minutes. Mice that received 
the team’s “vaccine” were unaffected when 
later given nicotine, running around with 
no change in blood pressure or heart rate. 
When Crystal’s team analyzed the animals’ 
blood samples, they found that 83% of nico-
tine in the serum was bound to the antibod-
ies made by the inserted gene, preventing it 
from reaching the brain and triggering the 
dopamine reward system. In the brain, nico-
tine concentrations were just 15% of that in 
untreated control animals.  
“It’s a second-generation vaccine for 
addictive molecules. It’s more elegant. It 
produces more antibody,” Crystal says, add-
ing that the virus carrying the monoclonal 
antibody gene is currently being tested in 
another gene therapy clinical trial, so he’s 
confi dent of its safety record.
A nicotine vaccine 
interests Big Pharma, 
Janda notes, “because 
there’s money in it.” 
Smoking causes about 
one in fi ve deaths in the 
United States each year, 
is responsible for 90% 
of lung cancer in men 
and 80% in women, and 
boosts the risk of stroke 
and heart disease two-
fold to fourfold. 
P h a r m a c e u t i c a l 
companies may indeed 
see a big market for a 
nicotine vaccine, but 
they’re not sure anyone 
can deliver a safe, effec-
tive product. “Novar-
tis has made some con-
tracts with biotech 
companies to develop 
antismoking vaccines,” 
says Rino Rappuoli, 
global head of vaccines 
research for Novartis 
Vaccines and Diagnos-
tics in Siena, Italy, “but 
there has not been much 
progress. Big compa-
nies rely on biotechs to 
derisk the sector.” As 
the stumbling efforts to 
immunize people from Alzheimer’s, obe-
sity, and smoking attest, however, develop-
ing vaccines for chronic diseases remains a 
risky proposition. 
–BIJAL TRIVEDI
Bijal Trivedi is a freelance writer in Washington, D.C.
An expanding epidemic. A vaccine that 
could reduce weight gain would have a 
domino effect on other chronic condi-
tions such as coronary heart disease, 
type 2 diabetes, and high blood pressure.
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